KINNATE BIOPHARMA INC (KNTE) Stock Price, Quote, News and Overview
NASDAQ:KNTE - Nasdaq - US49705R1059 - Common Stock - Currency: USD
KNTE Quote, Performance and Key Statistics
2.65
-0.01 (-0.38%)
The current stock price of KNTE is 2.65 USD. In the past month the price increased by 2.32%. In the past year, price decreased by -56.63%.
KNTE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 323.71B | ||
| AMGN | AMGEN INC | 13.09 | 146.07B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.56B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.81B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6.17 | 26.10B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.94B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About KNTE
Company Profile
Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. The company is focused on the discovery, design and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Its lead product candidate is exarafenib (KIN-2787), which is a Rapidly Accelerated Fibrosarcoma (RAF) inhibitor in development for the treatment of patients with lung cancer, melanoma and other solid tumors. Its second product candidate is KIN-3248, a Fibroblast Growth Factor Receptors (FGFR) inhibitor, designed for the treatment of patients with intrahepatic cholangiocarcinoma (ICC). KIN-3248 is designed to address clinically observed kinase domain mutations in FGFR2 and FGFR3. The company is also advancing other small molecule research programs, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor in its KIN004 program for the treatment of ovarian carcinoma (OC), triple-negative breast cancer (TNBC) and metastatic castration-resistant prostate cancer (mCRPC).
Company Info
KINNATE BIOPHARMA INC
11975 El Camino Real, Ste 101, Suite 101
San Diego CALIFORNIA 92130 US
CEO: Nima Farzan
Employees: 84
Phone: 18582994699
KINNATE BIOPHARMA INC / KNTE FAQ
What is the stock price of KINNATE BIOPHARMA INC today?
The current stock price of KNTE is 2.65 USD. The price decreased by -0.38% in the last trading session.
What is the ticker symbol for KINNATE BIOPHARMA INC stock?
The exchange symbol of KINNATE BIOPHARMA INC is KNTE and it is listed on the Nasdaq exchange.
On which exchange is KNTE stock listed?
KNTE stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for KINNATE BIOPHARMA INC stock?
10 analysts have analysed KNTE and the average price target is 2.41 USD. This implies a price decrease of -9.04% is expected in the next year compared to the current price of 2.65. Check the KINNATE BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is KINNATE BIOPHARMA INC worth?
KINNATE BIOPHARMA INC (KNTE) has a market capitalization of 125.00M USD. This makes KNTE a Micro Cap stock.
How many employees does KINNATE BIOPHARMA INC have?
KINNATE BIOPHARMA INC (KNTE) currently has 84 employees.
What are the support and resistance levels for KINNATE BIOPHARMA INC (KNTE) stock?
KINNATE BIOPHARMA INC (KNTE) has a support level at 2.65 and a resistance level at 2.67. Check the full technical report for a detailed analysis of KNTE support and resistance levels.
Should I buy KINNATE BIOPHARMA INC (KNTE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of KNTE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of KNTE, evaluating the profitability, health, valuation and growth aspects
- KINNATE BIOPHARMA INC (KNTE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- KINNATE BIOPHARMA INC (KNTE) Sales and EPS estimates to see what analysts future expectations are.
- KINNATE BIOPHARMA INC (KNTE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- KINNATE BIOPHARMA INC (KNTE) Insider and Institutional Ownership to learn about the owners and their transactions.
- KINNATE BIOPHARMA INC (KNTE) Stock Chart to make your own analysis
- KINNATE BIOPHARMA INC (KNTE) Latest news and press-releases to stay up to date.
Does KINNATE BIOPHARMA INC (KNTE) stock pay dividends?
KNTE does not pay a dividend.
When does KINNATE BIOPHARMA INC (KNTE) report earnings?
KINNATE BIOPHARMA INC (KNTE) will report earnings on 2024-05-09, after the market close.
What is the Price/Earnings (PE) ratio of KINNATE BIOPHARMA INC (KNTE)?
KINNATE BIOPHARMA INC (KNTE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.42).
KNTE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to KNTE. When comparing the yearly performance of all stocks, KNTE is a bad performer in the overall market: 86.11% of all stocks are doing better.
KNTE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KNTE. KNTE has a great financial health rating, but its profitability evaluates not so good.
KNTE Financial Highlights
Over the last trailing twelve months KNTE reported a non-GAAP Earnings per Share(EPS) of -2.42. The EPS increased by 8.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -64.89% | ||
| ROE | -70.7% | ||
| Debt/Equity | 0 |
KNTE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to KNTE. The Buy consensus is the average rating of analysts ratings from 10 analysts.